Instructions for Dostinex (Cabergoline) pills
English product name
Dostinex®
Release form
Tablets
Description:
The tablets are white, flat and elongated, with the marking "P" and "U" separated by a groove on one side and "700" with short notches on the top and bottom of the central number "0" on the other side.
1 tab.
kabergolin 0.5 mg
Auxiliary substances: lactose - 75.9 mg, leucine - 3.6 mg.
2 pcs. - high-density polyethylene bottles (1) - cardboard packs with first opening control.
8 pcs. - high-density polyethylene bottles (1) - cardboard packs with first opening control.
ATC codes
G02CB03 Cabergoline
Clinical-pharmacological groups / Group affiliation Dostinex
Dopamine receptor agonist. Prolactin secretion inhibitor
Active substance
kabergolin
Pharmacotherapy group Dostinex:
Dopamine receptor agonist
Storage Conditions:
The drug Dostinex should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.
Testimony Dostinex:
- Prevention of physiological lactation after childbirth;
- Suppression of established postnatal lactation;
- Treatment of hyperprolactinemia disorders,
- including amenorrhea, oligomenorrhea, anovulation and galactorrhea;
- prolactin-secreting pituitary adenomas (micro- and macroprolactinomas),
- idiopathic hyperprolactinemia, empty-saddle syndrome in combination with hyperprolactinemia.
Method of use, course and dosage:
Taken inside, while eating.
Prevent lactation: one mg (two tabs of 0.5 mg) once on the first day after delivery (preferably with the first meal after delivery).
Suppressed established lactation:
0.25 mg (1/2 tb) 2 times/day every 12 hours for two days (total dose is 1 mg). In order to reduce the risk of orthostatic arterial hypotension in women, a single dose of cabergoline should not exceed 0.25 mg.
Treatment of hyperprolactinemia disorders:
The recommended starting dose is 0.5 mg per week for one dose (one tabb 0.5 mg) or two doses (1/2 tabb 0.5 mg, for example, on Monday and Thursday).
The weekly dose should be increased gradually by 0.5 mg at one month intervals until the optimum therapeutic effect is achieved. The therapeutic dose is usually one mg per week, but can range from 0.25 mg to two mg per week. The maximum dose for hyperprolactinemia patients is 4.5 mg per week.
Depending on the tolerability, the weekly dose can be taken once or divided into two or more doses per week.
Dividing the weekly dose into several doses is recommended when the dose is more than one mg per week.
Application in elderly patients
Due to indications of cabergoline use, the experience of using the drug Dostinex in elderly patients is extremely limited.
Use in children
The use of the preparation in children and adolescents under 16 years of age is contraindicated.
- Nosology (ICD codes)
- D35.2
- Benign Pituitary Neoplasm
- E22.1
- Hyperprolactinemia
- E23.6
- Other pituitary diseases
- N64.3
- Non-childbearing galactoria
- N91
- No menstruation, scarce and rare menstruation
- N97.0
- Female infertility due to lack of ovulation
- Z39.1
- Assistance and examination of nursing mothers
Pharmacological effect Dostinex:
Cabergolin is a dopaminergic derivative of ergolin, characterized by a pronounced and long-lasting prolactin lowering action caused by direct stimulation of dopamine D2 receptors of pituitary lactotropic cells. Furthermore, when taken at doses higher than these to reduce the concentration of prolactin in blood plasma, cabergolin has a central dopaminergic effect, due to the stimulation of dopamine D2 receptors.
The reduction of prolactin in blood plasma is observed within 3 hours after taking the drug Dostinex and persists for 7-28 days in healthy volunteers and patients with hyperprolactin, and up to 14-21 days in women in the postpartum period.